GLP-1RAs, including semaglutide and liraglutide, are frequently used today for the treatment of type 2 diabetes and obesity. A recent study investigated whether and how overweight and/or diabetic psoriasis patients benefit from treatment with GLP-1RAs. Initial results were presented at this year’s congress of the European Academy of Dermatology and Venereology (EADV).
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Alternative to insulin and GLP1
From the β-cell to the center: the versatile role of amylin
- Diabetic ketoacidosis
Recommendations for action in practice
- Severe acute pancreatitis
COX-2 inhibition alleviates inflammation and improves outcomes
- Ulcerative colitis
Rgs14 protein can worsen the severity
- Mastocytosis
Innovative pathogenesis-based therapeutic approaches in the pipeline
- Psychooncology
Communication as the key to therapy adherence
- Participation of the patient
Adherence in psychiatry
- Acute myeloid leukemia